Aires Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2006-12-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.airespharma.com
Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2014-04-09
- Lead Sponsor
- Aires Pharmaceuticals, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT01725269
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Phase 2
Terminated
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: AIR001 (sodium nitrite inhalation solution)
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2014-04-09
- Lead Sponsor
- Aires Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01725256
- Locations
- 🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects
Phase 1
Completed
- Conditions
- Pulmonary HypertensionPulmonary Arterial Hypertension
- Interventions
- Drug: 15 mg sodium nitrite inhalation solutionDrug: 25% MTD sodium nitrite inhalation solutionDrug: 90 mg sodium nitrite inhalation solutionDrug: 45 mg sodium nitrite inhalation solutionDrug: 120 mg sodium nitrite inhalation solution
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2012-11-09
- Lead Sponsor
- Aires Pharmaceuticals, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT01409122
- Locations
- 🇺🇸
PAREXEL International Early Phase Clinical Unit - Baltimore, Baltimore, Maryland, United States
Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers
Phase 1
Completed
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo and AIR001 Inhalation Solution (Expansion arm)
- First Posted Date
- 2008-12-25
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Aires Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT00814645
- Locations
- 🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath